Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...

A primary catalyst for the sector stems from evolving regulations. The FDA Modernization Act 2.0 is creating a favorable environment by encouraging the use of advanced digital models over traditional ...

Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc.

Absci Corp (NASDAQ:ABSI) shares are trading lower by 9.4% to $4.46 Wednesday afternoon after the company announced an offering of 16.7 million shares at $4.50 per share. The underwriters have an ...

HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $7.00 price target ...

Advanced Micro Devices Inc. today announced that it has invested $20 million in Absci Corp., a company using artificial intelligence to develop new medicines. AMD will also partner with the company to ...

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...